These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 22008594)

  • 1. Ceftaroline (Teflaro): a new cephalosporin.
    Belavic JM
    Nurse Pract; 2011 Nov; 36(11):12-3. PubMed ID: 22008594
    [No Abstract]   [Full Text] [Related]  

  • 2. Ceftaroline fosamil (Teflaro) - a new IV cephalosporin.
    Med Lett Drugs Ther; 2011 Jan; 53(1356):5-6. PubMed ID: 21252841
    [No Abstract]   [Full Text] [Related]  

  • 3. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Jorgenson MR; DePestel DD; Carver PL
    Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients.
    Udeani G; Evans J; Cole P; Friedland HD
    Hosp Pract (1995); 2014 Aug; 42(3):109-15. PubMed ID: 25255412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ceftaroline fosamil, a broad spectrum cephalosporin antibiotic for the treatment of community-acquired pneumonia and complicated skin and skin structure infections].
    Nikitin AV
    Antibiot Khimioter; 2011; 56(7-8):47-9. PubMed ID: 22359871
    [No Abstract]   [Full Text] [Related]  

  • 6. Ceftaroline fosamil: drug profile and clinical data.
    Kanafani ZA
    Future Microbiol; 2011 Jan; 6(1):9-18. PubMed ID: 21162631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection.
    Casapao AM; Steed ME; Levine DP; Rybak MJ
    Expert Opin Pharmacother; 2012 Jun; 13(8):1177-86. PubMed ID: 22594846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
    File TM; Low DE; Eckburg PB; Talbot GH; Friedland HD; Lee J; Llorens L; Critchley I; Thye D
    Clin Infect Dis; 2010 Dec; 51(12):1395-405. PubMed ID: 21067350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Saravolatz LD; Stein GE; Johnson LB
    Clin Infect Dis; 2011 May; 52(9):1156-63. PubMed ID: 21467022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA.
    Garrison MW; Kawamura NM; Wen MM
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1087-103. PubMed ID: 23167512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Zinforo™ (ceftaroline fosamil)--A new beta-lactam-cephalosporin with MRSA activity].
    Welte T
    Dtsch Med Wochenschr; 2014 Nov; 139 Suppl 3():S89-90. PubMed ID: 25429539
    [No Abstract]   [Full Text] [Related]  

  • 12. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Wilcox MH; Corey GR; Talbot GH; Thye D; Friedland D; Baculik T;
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv53-iv65. PubMed ID: 21115455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftaroline: a comprehensive update.
    Kaushik D; Rathi S; Jain A
    Int J Antimicrob Agents; 2011 May; 37(5):389-95. PubMed ID: 21420284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftaroline for complicated skin and skin-structure infections.
    Nannini EC; Stryjewski ME; Corey GR
    Expert Opin Pharmacother; 2010 May; 11(7):1197-206. PubMed ID: 20402556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.
    Beresford E; Biek D; Jandourek A; Mawal Y; Riccobene T; Friedland HD
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):123-35. PubMed ID: 24494793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftaroline fosamil: a new broad-spectrum cephalosporin.
    Laudano JB
    J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii11-8. PubMed ID: 21482565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP).
    Guervil DJ; Kaye KS; Hassoun A; Cole P; Huang XY; Friedland HD
    J Chemother; 2016 Jun; 28(3):180-6. PubMed ID: 25817579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
    Corey GR; Wilcox MH; Talbot GH; Thye D; Friedland D; Baculik T;
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv41-51. PubMed ID: 21115454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients.
    Evans JD; Udeani G; Cole P; Friedland HD
    Postgrad Med; 2014 Sep; 126(5):128-34. PubMed ID: 25295657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update for community-acquired bacterial pneumonia pharmacotherapy: what's new and where does it fit?
    DeBellis HF; Jones MC; Kincaid SE
    J Pharm Pract; 2012 Dec; 25(6):569-75. PubMed ID: 23065389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.